“The forward momentum continues at Nuvalent (NUVL), with both of our parallel-lead programs advancing toward key US regulatory milestones and the opportunity to bring our first new medicine to patients this year,” said James Porter, Chief Executive Officer of Nuvalent. “We recently submitted our NDA for neladalkib in TKI pre-treated ALK-positive NSCLC and are continuing to build our commercial infrastructure in preparation for a potential US launch of zidesamtinib in TKI pre-treated ROS1-positive NSCLC, if approved.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Guardant Health announces multi-year strategic collaboration with Nuvalent
- Nuvalent Buy Rating: Zidesamtinib’s Differentiated ROS1 CNS Efficacy Supports $155 Target Price
- Nuvalent to present preclinical data for zidesamtinib at AACR meeting
- Nuvalent: Buy Rating on Strong Pipeline Execution, Dual NDA Momentum, and Solid Cash Runway in Targeted NSCLC
- Nuvalent Files FDA Application for Lung Cancer Therapy